Tenofovir Disoproxil Fumarate vs. Entecavir in Chronic Hepatitis B Patients With Partial Virologic Response to Entecavir
Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
Entecavir, a potent antiviral agent, has been widely used for treatment-naïve chronic
hepatitis B patients. However, about 20% of patients showed partial virologic response after
2 year of entecavir therapy (33% in HBeAg positive, 10% in HBeAg negative patients).
Tenofovir is a nucleotide analogue with more potent antiviral activity. In addition, there is
no cross resistance between the two drugs. Therefore it is assumed that tenofovir would be
effective in the treatment of chronic hepatitis B patients who shows partial virologic
response (detectable HBV DNA by real time PCR after 12 months of treatment) despite treatment
with entecavir. In this study, we will compare the efficacy of switching to tenofovir with
continuing entecavir in patients who shows partial virologic response to entecavir.